public markets through IPOs in a broad range of market conditions. Examples of this type of later stage investment in the New Leaf portfolio include Acadia Pharmaceuticals (NLV-IIL NASDAQ: ACAD, exited at 2.5x), Phase III, focused on psychosis associated with neurodegenerative diseases, Durata Therapeutics (NLV-II, priv